Skip to main content
OpenTrials
Completed

NCT Number: NCT02538575

6 Minute Walk Test in Cystic Fibrosis

The purpose of this study is to determine whether the 6-minute walk test (6MWT) could be a prognostic factor for cystic fibrosis patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hôpital Cochin, service de pneumologie

Paris, 75014, France

About this study

The 6-minute walk test is a simple exercise test, reproducing a daily physical activity. The utility of this test is described in several chronic lung diseases (chronic obstructive pulmonary disease, idiopathic pulmonary arterial hypertension). The distance performed during the 6MWT and / or desaturation during the 6MWT is a prognostic factor that contributes to the assessment of patients for lung transplantation indication.

The 6MWT is practiced routinely in cystic fibrosis centers but its usefulness in this disease has not been shown. Also the results of this test are not part of the decision-making criteria for lung transplantation.

A single-center study performed in adults CRCM at Cochin Hospital suggests the prognostic value of the 6MWT in patients with adult's cystic fibrosis.

The principal objective of this study is to assess the prognostic of 6MWT as part of the cystic fibrosis. The primary endpoint will be to assess the survival without lung transplant during the follow up period of 3 years. In this context, this prognostic tool could be used to help to determine the best time to consider a lung transplant in cystic fibrosis patient.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with Cystic Fibrosis (bronchiectasis with presence of two mutations in the CFTR gene and / or positive sweat test.
  • Patients aged 18 year or older.
  • Pre-bronchodilator FEV1 FEV1 ≤ 60% from theoretical value: this FEV1 limits is proposed following the results from our published study (Martin et al. 2013) showing that desaturation during 6MWT and a distance ≤ 475m performed, are almost exclusively found in patients with FEV1 ≤ 60% .
  • Stable health status ( >15 days after the start of treatment of a respiratory exacerbation
  • No indications against the walking test:

Left uncontrolled heart failure Severe aortic stenosis acute endocarditis syncope Symptomatic severe arrhythmia stable angina Myocardial infarction <5 days Acute respiratory distress Resting SpO2≤85% pulmonary edema Uncontrolled asthma Arterial or venous thrombosis of the lower limbs, Severe acute condition that may interfere with the exercise performance (infections, renal failure, hyperthyroidism, unable to cooperate, severe pulmonary arterial hypertension, severe systemic blood pressure (Systolic blood pressure >200 mm Hg and / or diastolic blood pressure >120 mm Hg))

Exclusion criteria

  • History of lung transplant
  • Oxygen Dependence (inability to achieve a 6-minute walk test in ambient air)
  • Any indication against walk test
  • Pregnant women, persons deprived of liberty, person under guardianship, person in emergency situation
  • Person not affiliated to social security system
  • Refusal to participate in the study

Treatment and study plan

6-minute walk test

Other

a walk of 6 minutes repeated twice in an interval of 30 minutes

Primary outcomes

  1. Survival without lung transplant

    Time frame: 3 years

Secondary outcomes

  1. distance traveled during the 6MWT

    Time frame: one day

  2. Oxygen desaturation (SpO2<90%) measured by a plethysmography exam during the 6MWT

    Time frame: one day

  3. Number of days of intravenous antibiotic therapy

    Time frame: 3 years

  4. Dyspnea questionnaire (mMRC scale)

    Time frame: once a year during 3 years

  5. Measure of the Quality of life (Cystic Fibrosis Questionnaire 14+, SF12)

    Time frame: once a year during 3 years

  6. Measure of Anxiety and Depression (Hospital Anxiety Depression HAD scale)

    Time frame: once a year during 3 years

  7. Measure of the Physical activity (Baecke questionnaire)

    Time frame: once a year during 3 years

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • Data analysis : EFFI-STAT (statistic expert)
  • Funding : Association Vaincre La Mucoviscidose
  • URC-CIC Paris Descartes Necker Cochin

Registry information

Official study title

Prognosis Contribution of the 6 Minute Walk Test in Cystic Fibrosis : Prospective Multicenter Study

Acronym: MUCO-TM6

Important dates

Study start
2016
Primary completion
2018
Study completion
2020
First posted
Sep 2, 2015
Registry last updated
Nov 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.